Market cap
₹69 Cr
Recently Viewed
Clear AllNSE: VINEETLAB | BSE: 543298
₹36.12
₹-0.62
(-1.69%)
As on 05-May-2026IST
Market cap
₹69 Cr
Revenue (TTM)
₹55 Cr
P/E Ratio
--
P/B Ratio
1.5
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
₹-10 Cr
ROE
-81.8 %
ROCE
-25.1 %
Industry P/E
34.69
EV/EBITDA
-30.8
Debt to Equity
2.7
Book Value
₹23.4
EPS
₹-11
Face value
10
Shares outstanding
19,206,266
CFO
₹30.38 Cr
EBITDA
₹19.87 Cr
Net Profit
₹-9.50 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Vineet Lab
| -1.8 | 22.4 | 10.0 | 33.4 | -3.2 | -- | -- |
|
BSE Healthcare
| 4.4 | 9.6 | 7.4 | 7.9 | 25.1 | 14.2 | 11.4 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Vineet Lab
| -25.4 | -27.7 | 29.1 | -22.9 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Vineet Lab
|
36.1 | 69.1 | 54.6 | -10.1 | -13.9 | -70.2 | -- | 1.5 |
| 1,076.6 | 13,190.5 | 2,512.3 | 543.7 | 28.3 | 19.3 | 24.3 | 4.2 | |
| 490.7 | 8,512.0 | 1,053.1 | 293.6 | 32.3 | 24.6 | 29 | 6.6 | |
| 1,184.8 | 12,393.4 | 1,158.7 | 309.6 | 31.9 | 17.3 | 39.7 | 6.6 | |
| 1,690.3 | 32,068.1 | 9,203.5 | 941.3 | 15.4 | 19.6 | 34.7 | 6.4 | |
| 382.8 | 4,170.1 | 159.3 | 47.8 | 39.0 | 18.6 | 87.3 | 15.1 | |
| 16,204.0 | 20,788.3 | 1,575.1 | 179.1 | 14.9 | 11.4 | 116.1 | 12.5 | |
| 882.1 | 4,060.1 | 588.5 | 102.9 | 22.1 | 12.7 | 40 | 4.8 | |
| 686.4 | 7,747.2 | 502.0 | 138.7 | -- | 32.8 | 55.9 | 8.9 | |
| 206.0 | 5,423.4 | 7.1 | -274.7 | -4,008.3 | -140.4 | -- | 8.2 |
No Review & Analysis are available.
Vineet Laboratories Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API), intermediates, and fine chemicals primarily in India. The company offers intermediates of Lopinavir, Ritonavir,... Efavirenz, Nadolol, Glimepiride, Celecoxib, Piroctone Olanine, and other API intermediates. It also provides fine chemicals and reagents, such as isopropyl-beta-d-thiogalactopyranoside, n-butyl lithium, 4-nitrophenyl phosphate disodium salt, 5-bromo-4-chloro-3-indolyl-beta-d-galactopyranoside, 5-acetyl thiophene-2-carboxilic acid, 4-chlorobutyryl chloride, n-butyl magnesium chloride, 3-furaldehyde, 3-bromofuran, n-butylnitrite, ethyldiazo acetate, phenylboronic acid, 6-aminouracil, and 1-methyl-imidazole-2-carboxaldehyde. The company was incorporated in 2016 and is based in Hyderabad, India. Read more
Incorporated
2016
Chairman
Dilip Vishnu Acharekar
Managing Director
Gaddam Venkata Ramana
Headquarters
Hyderabad, Telangana
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Vineet Laboratories Ltd is ₹36.12 (NSE) and ₹36.00 (BSE) as of 05-May-2026 IST. Vineet Laboratories Ltd has given a return of -3.17% in the last 3 years.
Since, TTM earnings of Vineet Laboratories Ltd is negative, P/E ratio is not available.
The P/B ratio of Vineet Laboratories Ltd is 1.54 times as on 05-May-2026, a 39 discount to its peers’ median range of 2.52 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
0.00
|
1.92
|
|
2024
|
44.25
|
1.31
|
|
2023
|
30.22
|
1.12
|
|
2022
|
6.58
|
1.32
|
|
2021
|
0.00
|
0.00
|
The 52-week high and low of Vineet Laboratories Ltd are Rs 43.50 and Rs 22.37 as of 05-May-2026.
Vineet Laboratories Ltd has a market capitalisation of ₹ 69 Cr as on 05-May-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Vineet Laboratories Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.